RE:Revenue sabre rattling for yearsWhat shareholders seem to forget, is they moved forward on revenue as a device after Ba contrast designation was changed from a drug. They invested heavily in this, then Bracco lobbied senate/congress and had all contrast switched to drug designation in the drug bill that passed. This was the set back the company on cash flow projections. It went from requireing a few million to move forward to a hell of allot more cash required to redo all thier work. The US market is the only market that matters in pharma for high margins. The only positive I see from that, is Bracco will go to great legths to protect their monopoly, this actually bodes well for the company, because they are not going to stop moving forward and the only option for Bracco now is to buy out Voy or loose market share. It will be interesting to see what financing is on the way. I bet September will be full of great news flow.
Lets not forget a new one of a kind pharma contrast drug is in the works as well. The future value on that is in the billions.